Fulranumab regulatory update

FDA's Arthritis Drugs Advisory Committee voted 21-0 that anti- nerve growth factor (NGF) agents should continue to be developed to treat osteoarthritis (OA) pain. Because the joint destruction was increased in patients taking anti-NGFs with NSAIDs, the

Read the full 372 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE